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Cardiac amyloidosis is characterised by the extracellular deposition of misfolded 
proteins in the heart with the pathognomonic histological property of green 
birefringence when viewed under cross polarised light after staining with Congo red(1).  
Although considered a rare disease, recent data suggest that cardiac amyloidosis is 
underappreciated as a cause of common cardiac diseases or syndromes(2). Recent 
advances in cardiac imaging, diagnostic strategies and therapies have improved the 
recognition and treatment of cardiac amyloidosis(1,2). 
The aim of this position paper by the European Society of Cardiology (ESC) Working 
Group on Myocardial and Pericardial Disease is to help cardiologists and other 
physicians in recognising, diagnosing and treating patients with cardiac amyloidosis. 
 
Definitions and classifications 
 
Types of cardiac amyloidosis:  
While more than 30 proteins are known to be capable of aggregating as amyloid in vivo, 
only 9 amyloidogenic proteins accumulate in the myocardium to cause significant 
cardiac disease(3). 
Nevertheless, some forms (AApoAI, AApoAII, AApoAIV, Aβ2M, AFib, AGel) are very rare 
and cardiac amyloidosis secondary to chronic inflammatory and infectious diseases (AA), 
although still encountered, is now much less frequent. Accordingly, >98% of currently 
diagnosed cardiac amyloidosis results from fibrils composed of monoclonal 
immunoglobulin light chains (AL) or transthyretin (ATTR), either in its hereditary (ATTRv) 
or acquired (ATTRwt) form. Table 1 describes the main characteristics of each type of 
cardiac amyloidosis. 
 
Definition of cardiac amyloidosis. Diagnostic criteria.  
Cardiac amyloidosis is diagnosed when amyloid fibrils are found within cardiac tissue. 
Both invasive and non-invasive diagnostic criteria have been proposed. Invasive 
diagnostic criteria apply to all forms of cardiac amyloidosis whereas non-invasive criteria 
are accepted only for ATTR (Figure 1). 
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Invasive diagnostic criteria 
Cardiac amyloidosis is confirmed when an endomyocardial biopsy demonstrates 
amyloid deposits after Congo red staining irrespective of the degree of left ventricle (LV) 
wall thickness. Identification of amyloid should be followed by classification of the 
amyloid fibril protein. Although the gold standard for defining the type of amyloid 
remains mass spectrometry, immunohistochemistry or immunoelectron microscopy are 
routinely employed for amyloid typing in specialised centres.(4) 
Diagnosis is also confirmed if amyloid deposits within an extra-cardiac biopsy are 
accompanied either by characteristic features of cardiac amyloidosis by 
echocardiography, in the absence of an alternative cause for increased LV wall thickness, 
or by characteristic features on cardiac magnetic resonance (CMR) (Table 2). 
A recent multicentre study has proposed an echocardiographic score to facilitate 
echocardiographic diagnosis of AL or ATTR amyloidosis in the presence of increased LV 
wall thickness.(5) Although not yet externally validated, a score  8 points in the presence 
of LV wall thickness  12 mm in combination with amyloid deposits in an extra-cardiac 
biopsy could also be considered diagnostic of cardiac amyloidosis (Table 2). 
 
Non-invasive diagnostic criteria 
Cardiac ATTR amyloidosis can be diagnosed in the absence of histology in the setting of 
typical echocardiographic/CMR findings when 99mTc-pyrophosphate (PYP), 99mTc-3,3-
diphosphono-1,2-propanodicarboxylic acid (DPD) or 99mTc-hydroxymethylene 
diphosphonate (HMDP) scintigraphy shows grade 2 or 3 myocardial uptake of 
radiotracer (Figure 2) and clonal dyscrasia is excluded by all the following tests: serum 
free light chain (FLC) assay, serum free light chain (FLC) assay, serum (SPIE) and urine 
(UPIE) protein electrophoresis with immunofixation).(6) The combination of SPIE, UPIE 
and quantification of serum FLC has a sensitivity of 99% for identifying abnormal 
proamyloidotic precursor in AL amyloidosis.(7) It is important to stress that serum and 
urine protein electrophoresis should always be performed with immunofixation to 
increase the sensitivity of the assays for detecting monoclonal proteins (Table 3). 
Interpretation of low-level monoclonal protein or mild elevations in the kappa:lambda 
ratio (FLC ratio) could be challenging. These findings can be encountered in patients with 
chronic kidney disease (CKD) or with monoclonal gammopathy of undetermined 
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significance (MGUS). In patients with CKD, as the glomerular filtration rate (GFR) 
declines, the renal clearance of polyclonal FLC decreases and serum concentrations 
rise.(8) The FLC ratio also varies as the GFR declines, but this depends on the FLC assay 
available (Freelite assay [Binding Site] or N Latex assay [Siemens]).(8) With the N Latex 
assay, the FLC ratio decreases as GFR declines but no reference range in CKD has yet 
been proposed. By contrast, with the most frequently used Freelite assay, FLC ratio 
increases as GFR declines and a ratio of 0.37 to 3.1 has been proposed to be normal in 
patients with CKD. No reference values are available according to the severity of CKD, 
but in patients with moderate CKD (eGFR < 45 mL/min/1.73 m2 by CKD-EPI formula) in 
the setting of a normal SPIE/UPIE, a FLC ratio up to 2.0 (or 3.1 if in dialysis) can typically 
be considered normal (Table 3). Otherwise, consultation with a haematologist is 
warranted.  
In the absence of a detectable monoclonal protein and/or an abnormal serum FLC ratio, 
the specificity of grade 2 or 3 bone scintigraphy for cardiac ATTR when the disease is 
suspected has been proposed to be almost 100%(6). Please note, however, that 
scintigraphy should always include SPECT to confirm that cardiac uptake corresponds to 
myocardium uptake and not from cardiac chambers (Table 4). Nevertheless, recent 
reports have shown that rare situations can also lead to positive cardiac uptake.(9) These 
situations should always be considered when interpreting scintigraphy results (Table 4).  
Once cardiac ATTR amyloidosis is confirmed, genetic counselling and testing should be 
performed to assess for the presence of TTR mutations in order to differentiate between 
ATTRwt and ATTRv. Genetic testing should be performed even in elderly patients, as a 











Essential concepts  
- Although 9 types of cardiac amyloidosis are known, AL and ATTR currently account 
for the vast majority of cardiac amyloidosis. 
- Both invasive and non-invasive diagnostic criteria are accepted to diagnose cardiac 
amyloidosis. While invasive diagnostic criteria apply to all forms of cardiac amyloidosis, 
non-invasive criteria are accepted only for ATTR. 
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Diagnosis of cardiac amyloidosis 
Diagnosis of cardiac amyloidosis includes two critical phases: 1) suspicious phase and 2) 
definite diagnosis phase. The latter phase also includes appropriate typing of the 
amyloid, which is critical to guide specific treatment. 
 
When to suspect cardiac amyloidosis 
Red flags 
Cardiac amyloidosis typically appears within a constellation of extracardiac signs and 
symptoms that are extremely useful to suspect the disease in the presence of 
compatible cardiac imaging findings. These signs and symptoms are termed “red flags” 
and include proteinuria (even mild), macroglossia, skin bruises and carpal tunnel 
syndrome, among others (Table 5). There are also various red flags at the cardiac level, 
such as heart failure (including disproportionately high NT-proBNP) that appears to be 
in disproportion to “objective” findings on echocardiogram, “unexplained” right heart 
failure in the presence of ostensibly “normal” ventricular and valvular function, or 
“idiopathic” pericardial effusion. Persistent troponin elevation, disproportionally low 
QRS voltage or early conduction system disease are also signs that could evoke cardiac 
amyloidosis (Table 5). 
 
Clinical scenarios  
In addition to cardiac and extracardiac findings fostering the suspicion, there are several 
clinical situations in which cardiac amyloidosis should always be considered.  
Cardiac disease in the presence of a typical systemic condition such as plasma cell 
dyscrasia, nephrotic syndrome, peripheral neuropathy or a chronic systemic 
inflammatory condition should prompt consideration of amyloidosis, particularly if 
compatible cardiac imaging findings are present.  
Increased wall thickness in a nondilated LV is a prominent characteristic of cardiac 
amyloidosis and should trigger further evaluation when found in elderly patients with 
common cardiac syndromes like heart failure with preserved ejection fraction, 
hypertrophic cardiomyopathy or severe aortic stenosis, particularly among those 
undergoing transcatheter aortic valve replacement(11-13).   
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As ATTR has been found in a significant number of patients (up to 7 to 19%) in the 
abovementioned clinical scenarios, and with the possibility of non-invasive diagnosis, 
we recommend ascertainment of cardiac amyloidosis in individuals with increased wall 
thickness with either heart failure, aortic stenosis or red flag signs/symptoms, 
particularly if older than 65 years (Figure 3).  
 
Diagnostic algorithm 
Once cardiac amyloidosis is suspected, a timely, definitive diagnosis should be obtained 
as patient outcomes depend largely on early initiation of therapy (particularly in AL). 
As the large majority of cases of cardiac amyloidosis are AL and ATTR, we propose a 
diagnostic algorithm focusing on identifying these subtypes by the initial use of 99mTc-
PYP, DPD or HMDP scintigraphy coupled to assessment for monoclonal proteins by SPIE, 
UPIE and quantification of serum FLC (Figure 4).  
 
The results of these tests could lead to 4 scenarios: 
1. Scintigraphy does not show cardiac uptake and assessments for monoclonal 
proteins are negative. There is a very low probability of cardiac amyloidosis and 
ATTR and AL amyloidosis are unlikely. An alternative diagnosis should be 
considered. Nevertheless, if suspicion persists, consider CMR followed by cardiac 
or extracardiac biopsy as bone scintigraphy could be negative in some ATTRv 
mutations (tracer uptake depends on TTR fibril composition) and in rare subtypes 
of cardiac amyloidosis (Table 5).  
2. Scintigraphy shows cardiac uptake and assessments for monoclonal proteins are 
negative. If cardiac uptake is grade 2 or 3, ATTR cardiac amyloidosis can be 
diagnosed. Proceed with genetic testing to differentiate between ATTRv and 
ATTRwt forms. In the case that cardiac uptake is grade 1, non-invasive diagnosis is 
not possible and histological confirmation of amyloid deposits (could be 
extracardiac) is required. 
3. Scintigraphy does not show cardiac uptake and at least one of the monoclonal 
protein tests is abnormal. AL amyloidosis has to be ruled-out promptly and CMR 
can be used to confirm cardiac involvement. If CMR findings do not support 
cardiac amyloidosis, the diagnosis is very unlikely. In the case that CMR findings 
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are supportive or inconclusive, cardiac or extracardiac histological demonstration 
of amyloid deposits is required to diagnose AL cardiac amyloidosis. Cardiac or 
other clinically-affected organ biopsy is recommended to avoid time delay to 
diagnosis and consultation with a haematologist is warranted.(14) If CMR cannot be 
performed promptly, consider performing biopsy directly. 
4. Scintigraphy shows cardiac uptake and at least one of the monoclonal protein 
tests is abnormal. ATTR amyloidosis with concomitant MGUS (or any 
haematological disorder that produces FLC), AL amyloidosis or coexistence of both 
AL and ATTR amyloidosis are possible in this scenario. Diagnosis of cardiac 











Outcome and prognosis 
 
Prognosis in cardiac amyloidosis 
Although different methods to prognosticate in cardiac amyloidosis have been 
proposed, the focus has moved to multiparametric biomarker-based prognostic scores, 
and biomarker-based staging systems have been developed for AL and ATTR cardiac 
amyloidosis (Table 6).(15-19)    
Available scoring systems have been constructed using parameters obtained "at 
presentation" and provide an initial prognostic stratification. The prognostic impact of 
any change of the scores during follow-up has not yet been validated, even though 
recent studies have shown promising results.(20) 
 
Essential concepts  
- Cardiac amyloidosis should be considered in patients with increased wall thickness in 
the presence of cardiac or extracardiac red flags and/or in specific clinical situations.  
- A diagnostic algorithm based initially on the use of bone scintigraphy coupled to 




Progression of cardiac amyloidosis  
While there have been multiple studies delineating baseline risk factors associated with 
adverse outcomes (principally mortality) in AL and ATTR, and data is emerging from the 
placebo arm of therapeutic trials(21), there is a dearth of published data on longitudinal 
aspects of disease progression and none that are population based without referral and 
ascertainment biases. In the era of emerging effective therapies, this is a major unmet 
need. 
 
Follow-up of patients with cardiac amyloidosis 
Although no studies have yet addressed the optimal follow-up scheme in patients with 
cardiac amyloidosis, a common scheme consists of 6-month visits with ECG and 
complete blood tests (including NT-proBNP and troponin) and yearly echocardiogram 
and 24-h Holter ECG. A summary of recommended follow-up tests can be found in Table 
7. 
 
Follow-up of mutation carriers and genetic counselling 
Genetic testing is recommended for relatives of patients with an inheritable form of 
cardiac amyloidosis. Such testing should occur along with genetic counselling of patients 
and their families. As all hereditary amyloidoses have an adult onset, genetic testing of 
minors is discouraged. Genetic testing could be offered during young adulthood if 
genetic information would seem useful to guide professional choices or for reproductive 
planning.  
As age of onset, clinical penetrance, and progression depend upon the variant, 
assessment of penetrance in allele carriers is generally recommended to start ~10 years 
prior to the age of diagnosis of affected members of the family (or other individuals with 
the same mutation), or as soon as symptoms compatible with amyloidosis develop 






Essential concepts  
- While several staging systems are available to facilitate prognosis, there are limited 
data on how to assess progression. In the era of emerging effective specific therapies, 
this is a major unmet need. 
- Follow-up of patients with cardiac amyloidosis and mutation carriers should be 




Treatment of cardiac amyloidosis involves two areas: 1) Treatment and prevention of 
complications; and 2) Stopping or delaying amyloid deposition by specific treatment.  
 
Treatment of complications and comorbidities 
Supportive care of patients with cardiac amyloidosis encompasses different clinical 
aspects including treatment of heart failure, arrhythmias, conduction disturbances, 
thromboembolism and concomitant presence of severe aortic stenosis (Figure 5).(23-25) 
 
Specific (disease-modifying) treatment 
Treating the process of amyloid deposition should target the production of amyloid 
precursor protein or the assembly of amyloid fibrils. 
 
AL amyloidosis    
Specific treatment in cardiac AL amyloidosis should be undertaken by multidisciplinary 
teams involving oncohaematology and cardiology specialists and, whenever possible, 
patients should be referred to specialised centres.(26)   
Patients with AL amyloidosis not only have a haematologic malignancy, but also their 
multiorgan involvement makes them particularly fragile and susceptible to treatment 
toxicity. Therapeutic approaches depend on risk assessment that are defined in many 
circumstances by the degree of cardiac involvement (Supplemental material Figure 1S) 
and cardiac response depends also on haematological response (Supplemental material 
Table 1S).(23,24) The role of the cardiologist in the specific treatment includes:  1. Cardiac 
assessment for initial haematologic strategies, including consideration of autologous 
stem cell transplantation (Supplemental material Table 2S), 2. Heart transplant 
evaluation 3. Cardiac monitoring during chemotherapy.  
 
ATTR amyloidosis 
There is an increasing availability of novel, effective, targeted therapeutic options for 
ATTRwt and ATTRv. A prompt diagnosis is essential to enable the timely treatment of 
neurological, cardiac and other systemic manifestations, as therapy is more effective in 
the early stages of the disease.(27-28) Effective therapies reduce the production of 
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mutated (liver transplantation) and overall TTR (genetic silencers) or stabilise circulating 
TTR molecules (stabilisers), preventing their dissociation or cleavage into amyloidogenic 
fragments (Figure 6). Several new compounds are under investigation, including agents 
directed to remove amyloid fibrils (Supplemental material). 
Current therapeutic alternatives distinguish between ATTRv and ATTRwt and, in the case 
of ATTRv, according to the presence of cardiomyopathy, polyneuropathy or both (Figure 
7). A detailed description of ATTR therapies that are either available or are being tested 
in phase III trials can be found in Supplemental material. Tafamidis should be generally 
considered the agent of choice in ATTR cardiac patients with reasonable expected 
survival while patisiran could be considered in ATTRv patients with cardiac involvement 















Organisation of patient care 
Collaboration between centres remains essential because not all centres can perform 
complex diagnostic techniques (such as endomyocardial biopsy and mass spectrometry) 
or prescribe disease-modifying therapies, and interaction between cardiologists, 
haematologists, transplant surgeons, neurologists, and other specialists could be 
needed. The best strategy for the management of patients with amyloidosis is not the 
“hub-and-spoke” model, but rather a network where centres can do at least some parts 
of the diagnostic workup, exchange opinions and information, and refer patients to 
Essential concepts  
- Management of cardiac amyloidosis involves treatment and prevention of 
complications, and halting or delaying amyloid deposition by specific treatments. 
- Specific pharmacologic treatments available for ATTR amyloidosis include stabilising 
molecules (tafamidis) and genetic silencers (patisiran and inotersen). 
- Tafamidis is currently the only drug that has shown efficacy in a randomised trial in 
patients with ATTRwt and ATTRv with cardiomyopathy, and should be considered in 
patients with reasonable expected survival. 
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regional or national referral centres for selected procedures or particularly complex 
decisions.  
 
Summary and future directions 
As knowledge evolves and new therapeutic alternatives to treat cardiac amyloidosis 
emerge, new areas of research and unsolved questions arise. Some of the grey zones 
and areas of active research are summarised in Table 8.  
It is expected that advances in the field will change the way we diagnose, prognosticate 
and treat cardiac amyloidosis in the next few years. Meanwhile, in this paper the 
Working Group on Myocardial and Pericardial Disease proposes an invasive and non-
invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to 
suspect the condition and proposes a diagnostic algorithm to aid diagnosis. 
Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an 
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Table 1. Amyloidosis subtypes that affect the heart. 
 
Table 2. Echocardiographic and CMR criteria for non-invasive and invasive (with 
extracardiac biopsy-proven amyloidosis) diagnosis of cardiac amyloidosis.   
 
Table 3. Serum and urine tests to rule out AL amyloidosis. 
 
Table 4. Possible false positives and false negatives of diphosphonate scintigraphy for 
detecting ATTR cardiac amyloidosis. 
 
Table 5. Cardiac and extracardiac amyloidosis Red Flags. 
 
Table 6. Prognostic staging scores in AL and ATTR amyloidosis. 
 
Table 7. Proposed follow-up schemes in cardiac amyloidosis. 
 









Figure 1. Invasive and non-invasive diagnosis of cardiac amyloidosis. 
 
Figure 2. Cardiac uptake grading in biphosponate scintigraphy. Grade 0: absence of 
tracer myocardial uptake and normal bone uptake; Grade 1: Myocardial uptake in a 
lower degree than at bone level; Grade 2: Similar myocardial and bone uptake; Grade 3: 
Myocardial uptake greater than bone with reduced/absent bone uptake.   
 
Figure 3. Screening for cardiac amyloidosis. 
 
Figure 4. Diagnostic algorithm for cardiac amyloidosis. ATTRv: hereditary TTR 
amyloidosis; ATTRwt: wild-type TTR amyloidosis; AL light chain amyloidosis; CMR: 
cardiac magnetic resonance. 
 
Figure 5. Treatment of cardiac complications and comorbidities in cardiac amyloidosis. 
AA: antiarrhythmic; ACEI: angiotensin converting enzyme inhibitors; AF: atrial 
fibrillation; ARB: Angiotensin receptor blockers; AS: aortic stenosis; CV: cardioversion; 
ICD: implantable cardiac defibrillator; LVAD: left ventricular assist device; PPM: 
Permanent pacemaker. 
 
Figure 6. Available and future disease modifying therapies in ATTR amyloidosis.  
 
Figure 7. Proposed therapeutic alternatives in ATTR patients.  
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